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Pluripotent Stem Cells: The Search for the
“Perfect” Source
Nancy M.P. King*, Christine Nero Coughlin** &
Anthony Atala***
Anyone who dreamed that the public controversy over
human embryonic stem cell (hESC) research had begun to die
down was rudely awakened by the decision in Sherley v.
Sebelius. 1 On August 23, District of Columbia District Court
Judge Royce Lamberth issued a preliminary injunction halting
federal funding of research using newly created hESC lines
until the plaintiffs’ challenge to the 2009 liberalization of
funding guidelines can be heard. 2 On September 9, 2010, the
Court of Appeals for the District of Columbia temporarily
stayed Judge Lamberth’s order, 3 and on September 28, 2010,
the Court of Appeals ordered that the appeal be expedited and
granted the Obama administration’s motion to permit federally
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1. Sherley v. Sebelius, 704 F. Supp. 2d 63 (D.D.C. 2010), appeal docketed,
No. 10-5287 (D.C. Cir. Sept. 9, 2010) (order granting preliminary injunction).
2. Id. at 66.
3. Sherley v. Sebelius, No. 10-5287 (D.C. Cir. Sept. 9, 2010).
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funded hESC research to go forward during the appeal. 4
This dispute over federal funding might seem relatively
insignificant at first. Since the enactment of the Dickey-Wicker
Amendment 5 restricting the availability of funds for hESC
research, many states have set aside funding for hESC
research 6 —in some cases in significant amounts. 7 Private
funding is also available from the pharmaceutical industry and
disease advocacy foundations. 8 Investigators and academic
medical centers have become accustomed to separating their
cell lines, equipment, and activities so that there is no
commingling of federally funded hESC research with hESC
research that cannot receive federal support. 9 And finally,
there are many alternate sources of highly pluripotent stem
cells, though the scientific and practical promise of these
sources is, as we shall see, highly variable.
Nonetheless, this renewed focus on the Dickey-Wicker
Amendment demonstrates both the sensitivity of hESC
research and the complexity of the science, ethics, and policy
surrounding research using all forms of human stem cells.
Even the most cursory examination of this wide-ranging area of
scientific progress and policy discussion illustrates the futility
of searching for the “perfect” stem cell source.
I.

A SHORT HISTORY

The Dickey-Wicker Amendment was initially enacted in
1996 as a rider to appropriations legislation passed by

4. Sherley v. Sebelius, No. 10-5287 (D.C. Cir. Sept. 28, 2010) (granting
defendants’ motion to stay pending appeal and expediting appeal).
5. Balanced Budget Downpayment Act, Pub. L. No. 104–99, § 128, 110
Stat. 26, 34 (1996).
6. See, e.g., CAL. CONST. art. XXXV (establishing the California Institute
for Regenerative Medicine and the state constitutional right to conduct stem
cell research); CONN. GEN. STAT. § 19a-32e (West Supp. 2010); MD. CODE ANN.
ECON. DEV. § 10-434 (LexisNexis 2008).
7. California Stem Cell Research and Cures Bond Act, CAL. HEALTH &
SAFETY CODE § 125291.30 (effective Nov. 3, 2004) (authorizing the issuance of
three billion dollars in bonds for the purposes of conducting stem cell
research).
8. See, e.g., Dena Davis & Debra Grega, Lines of Communication:
Advances in Stem Cell Policy, 23 J. L. & HEALTH 29, 35 (2010).
9. National Institutes of Health Guidelines for Human Stem Cell
Research, 74 Fed. Reg. 32,170, 32,171–73 (July 7, 2009), available at
http://stemcells.nih.gov/policy/2009guidelines.htm.
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Congress in 1995. 10 It has been reenacted yearly since then.
The amendment prohibits the Department of Health and
Human Services from using appropriated funds for “(1) the
creation of a human embryo or embryos for research purposes;
or (2) research in which a human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of injury or
death greater than that allowed for research on fetusesin utero
. . . .” 11 The amendment defines a human embryo as any
organism “derived by fertilization, parthenogenesis, cloning, or
any other means from one or more human gametes.” 12
In 2001, President George W. Bush instituted a policy
permitting limited federal funding for research using hESC
lines that existed as of August ninth of that year. 13 Later, he
twice vetoed legislation to expand federal financing for hESC
research, 14 and issued an Executive Order calling for further
research on alternative sources of pluripotent stem cells. 15
When Bush’s policy was instituted, the NIH estimated that 64
lines were available for use. 16 Late in his term, however, there
were only about 20 embryonic stem cell lines approved for use
in federally funded studies. Many of these lines were
considered to be contaminated, to lack genetic diversity, or to
be otherwise insufficient for medical research. 17 Legislation to
change the date by which hESC lines must have been created
to be used in federally funded research repeatedly failed in
Congress during the Bush Administration.

10. Balanced Budget Downpayment Act § 128.
11. Id.
12. Id.
13. Address to the Nation on Stem Cell Research, 2 PUB. PAPERS 953,
955–56 (Aug. 9, 2001).
14. President’s Message to the Senate Returning Without Approval the
“Stem Cell Research Enhancement Act of 2007,” 43 WEEKLY COMP. PRES.
DOC. 833 (June 20, 2007); George W. Bush, President’s Message to the House
of Representatives Returning Without Approval the “Stem Cell Research
Enhancement Act of 2005,” 42 WEEKLY COMP. PRES. DOC. 1365 (July 19,
2006).
15. Exec. Order No. 13,435, 72 Fed. Reg. 34,591 (June 20, 2007).
16. John A. Robertson, Embryo Stem Cell Research: Ten Years of
Controversy, 38 J.L. MED. & ETHICS 191, 195 n.26 (2010).
17. E.g., Ruth R. Faden et al., Public Stem Cell Banks: Considerations of
Justice in Stem Cell Research and Therapy, 33 HASTINGS CENTER REP. 13, 13–
27 (2003); Stephen S. Hall, Stem Cells: A Status Report, 36 HASTINGS CENTER
REP. 16, 16–22 (2006); Annie D. Lyerly & Ruth R. Faden, Embryonic Stem
Cells: Willingness to Donate Frozen Embryos for Stem Cell Research, 317
SCIENCE 46, 46–47 (2007); Robertson, supra note 16, at 195 n.26.
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Thus, when President Obama issued a new Executive
Order permitting federal funding of research using newly
created cell lines from embryos originally created for in vitro
fertilization and later donated for research, 18 the change was
viewed as a simple modification of the date by which approved
stem cell lines could be created. 19 The source of embryos was
considered largely uncontroversial because the embryos were
not created for research and would otherwise be discarded or
stored indefinitely. Concerns remained that the number of
embryos available for research as a result of in vitro
fertilization might not make available a sufficient number of
optimally robust cell lines. 20 Still, it was not anticipated that
the interpretation of the Dickey-Wicker amendment’s language
would become a source of controversy.
However the Sherley v. Sebelius litigation is ultimately
resolved, it is clear that disagreement and concern about the
status of embryos and divergent views among scientists 21 and
the public 22 about morally appropriate sources of and uses for
hESCs will persist. 23 Although new sources of potentially
useful stem cells are hinted at almost daily in both the
scientific literature and the popular press, 24 profound optimism
about the therapeutic promise of hESCs coexists with
uncertainty about when that promise will be realized, ensuring
that scientists will continue their quest for better sources of
pluripotent stem cells.

18. Exec. Order No. 13,505, 74 Fed. Reg. 10,667, 10,668 (Mar. 9, 2009).
19. See generally National Institutes of Health Guidelines for Human
Stem Cell Research, supra note 9, at 32,173.
20. See Faden et al., supra note 17, at 13–27; Lyerly & Faden, supra note
17, at 46–47. See also David I. Hoffman et al., Cryopreserved Embryos in the
United States and Their Availability for Research, 79 FERTILITY & STERILITY
1063, 1063–69 (2003).
21. See generally S.P. Wainwright, et al., Ethical Boundary-work in the
Embryonic Stem Cell Laboratory, 28 SOC. HEALTH & ILLNESS 732, 744–45
(2006).
22. Lyerly & Faden, supra note 17, at 46–47.
23. See generally CYNTHIA B. COHEN, RENEWING THE STUFF OF LIFE:
STEM CELLS, ETHICS, AND PUBLIC POLICY (2007).
24. Macro Seandel et al., Generation of Functional Multipotent Adult
Stem Cells from GPR1251 Germline Progenitors, 449 NATURE 346, 346–350
(2007).

2011]

PLURIPOTENT STEM CELLS

719

II. hESCS IN BRIEF
In 1981, pluripotent cells were found in the inner cell mass
of the mouse embryo, and the term “embryonic stem cell” was
coined. 25 The ability to retrieve human embryonic stem cells
was described in 1998. 26 These cells are able to differentiate
into all cells of the human body, excluding placental cells (only
cells from the morula are totipotent; that is, able to develop
into all cells of the human body). Human embryonic stem cells
are highly versatile, able to give rise to all types of cells and to
be “immortalized,” or perpetually propagated in a cell line. 27
Their versatility makes them valuable for research and
treatment. However, they also have the intrinsic property of
forming teratoma tumors. 28
Ethical and policy arguments about the legal and moral
status of the embryo and preembryo are so familiar to most of
us that they no longer engage the intellect, but only serve to
harden apparently irreconcilable viewpoints. Each new
alternative source of highly multipotent stem cells seems to
alter the balance of arguments only slightly, exchanging some
concerns for others but never changing the moral landscape
enough to change minds. 29
Opponents of hESC research posit that all human zygotes
and embryos deserve significant protections because of their
potential for human development, regardless of whether that
potential will ever be realized. 30 While each cell in a zygote, or
very early embryo, is totipotent, that is, fully able to develop
into a complete embryo, the cells and cell lines derived from
human embryos are instead pluripotent: highly versatile but
not able to become new embryos. For this reason, contemporary

25. Gail R. Martin, Isolation of a Pluripotent Cell Line from Early Mouse
Embryos Cultured in Medium Conditioned by Teratocarcinoma Stem Cells, 78
PROC. NAT’L ACAD. SCI. U.S. 7634, 7635–38 (1981).
26. James A. Thomson et al., Embryonic Stem Cell Lines Derived from
Human Blastocysts, 282 SCIENCE 1145, 1145–46 (1998).
27. Junying Yu & James A. Thomson, Embryonic Stem Cells, as reprinted
in NAT’L INSTS. OF HEALTH, REGENERATIVE MEDICINE 1 (2006),
http://stemcells.nih.gov/staticresources/info/scireport/PDFs/Regenerative_Medi
cine_2006.pdf.
28. Davor Solter, From Teratocarcinomas to Embryonic Stem Cells and
Beyond: A History of Embryonic Stem Cell Research, 7 NATURE REV. GENETICS
319, 319–20 (2006).
29. See generally COHEN, supra note 23.
30. Russell Korobkin, Stem Cell Research and the Cloning Wars, 18 STAN.
L. & POL’Y REV. 161, 171 (2007).
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arguments in opposition to hESC research focus on the
destruction of embryos capable of developing into adult
humans, rather than on the moral status of the hESCs
themselves. 31
In contrast, proponents of hESC research employ a range
of deontological and consequentialist arguments, from the
proposition that human embryos should be viewed as biological
property, afforded no special protection, to holding that human
embryos should be afforded an intermediate moral status with
some special protections, but not a status equivalent to that of
a living infant or adult human. 32 Terms like ‘spare,’ ‘extra,’
‘leftover,’ ‘discarded,’ ‘abandoned,’ and ‘unwanted’ are used to
characterize human embryos created for assisted reproduction
but frozen and unused. A utilitarian calculus is often employed
to justify using these embryos—the most commonly discussed
potential source of new hESC lines, and the source referenced
in President Obama’s Executive Order and the revised 2009
Guidelines—in research. Many couples who have attempted in
vitro fertilization have expressed willingness to donate frozen
embryos for this purpose. 33
III. ALTERNATIVE SOURCES
Sherley v. Sebelius has now redoubled attention to deriving
highly pluripotent stem cell lines in ways that do not destroy
human embryos. These methods can be organized into several
categories: (1) somatic cell reprogramming; (2) other nonembryonic sources; (3) employing artificial and asexual
methods to create embryos; and (4) extracting hESCs from
embryos without embryo destruction. Each method shows
considerable promise, and each raises scientific, ethical, and
policy questions of its own.
A. SOMATIC CELL REPROGRAMMING: INDUCED PLURIPOTENT
STEM CELLS
The newest and, to many, the most exciting alternative to
hESC research is the development of pluripotent cells through
somatic stem cell reprogramming. In this process, either
31. See generally COHEN, supra note 23.
32. John A. Robertson, Ethics and Policy in Embryonic Stem Cell
Research, 9 KENNEDY INST. ETHICS J. 109, 110–130 (June 1999).
33. Lyerly & Faden, supra note 17, at 46–47.
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somatic cells or determined stem cells are stimulated by the
introduction of genetic material to evolve backward to a state of
pluripotency. The resulting induced pluripotent stem cells
(iPSCs) can then be grown into cell lines. 34 This process mimics
the limb regeneration capacities of some amphibians. 35 The
most significant moral concern that has been raised about this
research is that the process could be pursued beyond
pluripotency to totipotency. This concern appears, however, to
be entirely speculative.
First created in 2007, 36 iPSCs hold great promise as an
alternative to hESCs. To create them, pluripotency is induced
in a somatic cell (or sometimes in a so-called “adult stem cell,”
which can generate a single cell type) by genetically
reprogramming it to dedifferentiate into a pluripotent state. In
a clinical setting, this method could facilitate the growth of
compatible cells, tissues, or organs from a patient’s own cells. 37
In a research setting, iPSC lines could facilitate the close study
of many genetic disorders and the genetic contributions to
common complex disorders. This technique thus has potential
uses very similar to those of somatic cell nuclear transfer,
without the need for oocytes. 38
Several scientific obstacles must be overcome, however,
before iPSCs can be demonstrated to be as useful as hESCs.
Safety is a key consideration in the process of generating
34. NAT’L RES. COUNCIL & INST. OF MED., FINAL REPORT OF THE
NATIONAL ACADEMIES’ HUMAN EMBRYONIC STEM CELL RESEARCH ADVISORY
COMMITTEE AND 2010 AMENDMENTS TO THE NATIONAL ACADEMIES’
GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH App’x C (2010)
[hereinafter GUIDELINES FOR HUMAN EMBRYONIC STEM CELL RESEARCH],
available at http://www.nap.edu/catalog.php?record_id=12923; Chad A. Cowan
et al., Nuclear Reprogramming of Somatic Cells After Fusion with Human
Embryonic Stem Cells, 309 SCIENCE 1369 (2005); Keisuke Okita et al.,
Generation of Germline-Competent Induced Pluripotent Stem Cells, 448
NATURE 313, 313–14 (2007); Marius Wernig et al., In Vitro Reprogramming of
Fibroblasts into a Pluripotent ES-Cell-Like State, 448 NATURE 318, 321–22
(2007).
35. Panagiotis A. Tsonis, Bridging Knowledge Gaps on the Long Road to
Regeneration: Classical Models Meet Stem Cell Manipulation and
Bioengineering, 7 MOLECULAR INTERVENTIONS 249, 249 (2007).
36. Yoshinori Yoshida & Shinya Yamanaka, Recent Stem Cell Advances:
Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell-Based
Regeneration, 122 CIRCULATION 80, 80 (2010).
37. George Q. Daley, Stem Cells: Roadmap to the Clinic, 120 J. CLINICAL
INVESTIGATION 8, 9 (2010); Christopher J. Lengner, iPS Cell Technology in
Regenerative Medicine, 1192 ANNALS N.Y. ACAD. SCI. 38, 39–40 (2010).
38. See infra Part III.C.1.
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iPSCs. Most current methods of iPSC creation require the
introduction of genetic material into the cell. This is often
achieved by using viral vectors, as in gene transfer research,
and thus introduces comparable risks, including the possibility
of inducing cancers through insertional mutagenesis. 39 Uses of
non-integrating vectors or removable viral vectors, non-viral
vectors, and non-genetic means of reprogramming cells to a
pluripotent state are in development in many laboratories. 40 In
a recent development, the use of non-integrating synthetic
messenger RNA for cell reprogramming appears potentially
safe and efficient. 41 The intrinsic propensity of iPSCs, like
hESCs, to form teratoma tumors, however, may still pose a
risk. 42 Some recent experiments show potential for
circumventing these issues, but any risk of tumorigenicity
remains a challenge. 43
Finally, because decades of research have established
hESCs as the researcher’s gold standard, even as iPSCs are
increasingly studied, hESCs will continue to be necessary in
research, particularly as controls. Accordingly, the ethical
concerns attending the use of hESCs are likely to accompany
much iPSC research for the time being. Many uncertainties
about the safety, effectiveness and cost of iPSC development
and use in research are yet to be determined.

39. See Salima Hacein-Bey-Abina et al., A Serious Adverse Event After
Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency,
348 NEW ENG. J. MED. 255, 255 (2003).
40. See Rudolf Jaenisch & Richard Young, Stem Cells, the Molecular
Circuitry of Pluripotency and Nuclear Reprogramming, 132 CELL 567, 576
(2008); Lengner, supra note 37, at 40; Wenlin Li et al., Generation of Rat and
Human Induced Pluripotent Stem Cells by Combining Genetic Reprogramming
and Chemical Inhibitors, 4 CELL STEM CELL 16, 18–19 (2009); Keisuke Okita
et al., Generation of Mouse Induced Pluripotent Stem Cells Without Viral
Vectors, 322 SCIENCE 949, 949–52 (2008); Takashi Tada, Genetic ModificationFree Reprogramming to Induced Pluripotent Cells: Fantasy or Reality?, 3 CELL
STEM CELL 121–22 (2008).
41. Luigi Warren et al., Highly Efficient Reprogramming to Pluripotency
and Directed Differentiation of Human Cells with Synthetic Modified mRNA, 7
CELL STEM CELL 1, 6–7 (2010).
42. See Andrew Pollack, Stem Cell Trial Wins Approval of F.D.A., N.Y.
TIMES, July 31, 2010, at B1.
43. See Lengner, supra note 37, at 39.
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B. NON-EMBRYONIC SOURCES: AMNIOTIC FLUID AND
PLACENTAL CHORIONIC VILLI
Scientists have also discovered that broadly multipotent
stem cells capable of extensive expansion in laboratory culture
have been isolated from what are often considered biological
waste products: amniotic fluid and placental chorionic villi, 44
and the stromal tissue of umbilical cord. 45 The discovery that
amniotic fluid and placental tissue yields stem cells that are
neither derived from nor capable of developing into a human
embryo, yet are far more malleable and versatile than
determined stem cells, 46 is an exciting research prospect. The
derivation of useful cell lines from non-embryonic sources does
not, however, eliminate all ethical issues attendant upon this
research. For example, concern exists that the desire to capture
and store amniotic fluid stem cells will result in an increase in
amniocentesis, which carries small but well-recognized risks of
morbidity. 47 However, similar cells can be obtained from the
placenta, which is more readily accessible after birth and is
also usually discarded. 48
The discovery of new sources of highly multipotent cells in
potentially abundant biological waste materials like amniotic
fluid and placenta presents the real possibility of creating
publicly accessible stem cell banks which, by virtue of their size
and completeness, could quickly amass stem cells in sufficient
number and diversity to provide very good (albeit not perfect)
matches for almost all of the human population. 49 Building on
the arguments for pooling and sharing stored umbilical cord
blood, the creation of a cord blood and amniotic fluid stem cell
bank would have great promise for research and, eventually,

44. M. Minhaj Siddiqui & Anthony Atala, Amniotic Fluid-Derived
Pluripotential Cells, in 2 HANDBOOK OF STEM CELLS 175, 178–79 (Robert
Lanza et al. eds., 2004); Ming-Song Tsai et al., Clonal Amniotic-Fluid Derived
Stem Cells Express Characteristics of Both Mesenchymal and Neural Stem
Cells, 74 BIOLOGY REPROD. 545, 550 (2006).
45. Alp Can & Sercin Karahuseyinoglu, Concise Review: Human
Umbilical Cord Stroma with Regard to the Source of Fetus-Derived Stem Cells,
25 STEM CELLS 2886, 2886–88 (2007).
46. Paolo De Coppi et al., Isolation of Amniotic Stem Cell Lines with
Potential for Therapy, 25 NATURE BIOTECH. 100, 100–06 (2007).
47. See, e.g., John W. Seeds, Diagnostic Mid Trimester Amniocentesis:
How Safe? 191 AM. J. OBSTET. GYNECOL. 608, 608-616 (2004).
48. De Coppi et al., supra note 46.
49. Faden et al., supra note 17, at 13.
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for treatment, without traditional ethical concerns. 50
Traditional objections, however, may simply be replaced by
concerns about stem cell banking, including questions about
collection protocols, consent for collection, and the development,
maintenance, and sharing of banked cells. Much work is
needed to ensure the appropriate establishment and operation
of amniotic fluid and placental stem cell banks. Systems for the
collection, storage, and use of stem cells of different types are
still in the early stages, both technologically and from a policy
standpoint. Scientific, practical, and ethical issues raised
include ensuring the broad availability of matches for those in
need, determining access for research and for therapeutic uses,
refining consent forms, information, and procedures, and
developing robust systems for confidentially labeling
biospecimens and linking them to the information needed for
research and treatment. These issues have been well-rehearsed
in cord blood banking but have not been solved or settled. 51
Future extensions to highly multipotent stem cells from
amniotic fluid and placenta may be easier in some respects—for
instance, the cells can be perpetuated and thus will not be used
up when samples are taken for a particular use. Other issues
may be more difficult. For example, the processing cost for
amniotic fluid stem cells may be nontrivial. In addition, since
amniotic fluid stem cells are expected to have a broader range
of potential uses, the desired scope of consent could be
controversially broad.
C. ASEXUAL METHODS USING OOCYTES: SOMATIC CELL
NUCLEAR TRANSFER, ALTERED NUCLEAR TRANSFER, AND
PARTHENOGENESIS
1. Somatic Cell Nuclear Transfer
Artificial and asexual methods of stimulating the human
oocyte to act like an embryo are yielding promising results. For

50. National Amniotic and Placental Stem Cell Bank Act of 2007, H.R.
1892, 110th Cong. (as introduced by Rep. Lipinski, McIntyre, Shuler,
Ellsworth, Melancon, and Donnelly on April 17, 2007); HOPE Act, S. 30, 110th
Cong. (as passed by Senate on April 11, 2007); Amniotic Fluid and Placental
Stem Cell Banking Act of 2007, S. 957, 110th Cong. (as introduced by Sen.
Burr and Coleman on March 22, 2007)/
51. E.g., Jeremy Sugarman et al., Ethical Issues in Umbilical Cord Blood
Banking, 278 J. AM. MED. ASS’N 938 (1997).
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example, in somatic cell nuclear transfer (SCNT), the nucleus
of an oocyte is removed, replaced with a cell from another
donor, and stimulated to engage in cell differentiation. 52 After
sufficient cell division, stem cells are extracted that are a
genetic match to the donor, thus making this process, like iPSC
creation, useful to study certain genetic diseases or to grow
tissues and organs that will not be rejected. 53 Concerns about
the use of SCNT include the need to use large numbers of
oocytes in order to produce a viable and stable stem cell line, 54
along with the issues of understanding, consent, and
voluntariness that accompany oocyte procurement. 55 This
method, moreover, uses the same principles as reproductive
cloning, giving rise to a slippery slope problem for some
opponents. 56 The possibility of using non-human oocytes could
resolve concerns about oocyte procurement, but raises other
questions of feasibility and the ethics of this type of chimera
creation. 57
2. Altered Nuclear Transfer
Scientists are therefore looking for ways to make
reproduction impossible from cloned embryos. With this
technology, called altered nuclear transfer (ANT), a gene that
helps with implantation is deactivated during the growth of the
blastocyst, but reactivated after harvesting stem cells in order
52. PRESIDENT’S COUNCIL ON BIOETHICS, MONITORING STEM CELL
RESEARCH
111–12
(2004),
available
at
http://bioethics.georgetown.edu/pcbe/reports/stemcell/pcbe_final_version_moni
toring_stem_cell_research.pdf.
53. Darwin J. Prockop, Embryonic Stem Cells Versus Adult Stem Cells:
Some Seemingly Simple Questions, in ESSENTIALS OF STEM CELL BIOLOGY
xxiii–xxiv (Robert Lanza et al. eds., 2006); Robert P. Lanza et al., Generation
of Histocompatible Tissues Using Nuclear Transplantation, 20 NATURE
BIOTECH. 689, 689–90 (2002).
54. David Magnus & Mildred K. Cho, Issues in Oocyte Donation for Stem
Cell Research, 308 SCIENCE 1747, 1747 (2005); Narumi Ogonuki et al., Early
Death of Mice Cloned from Somatic Cells, 30 NATURE GENETICS 253, 253
(2002).
55. Josephine Johnston, Paying Egg Donors: Exploring the Arguments, 36
HASTINGS CENTER REP. 28, 28–31 (2006); John A. Robertson, Technology and
Motherhood: Legal and Ethical Issues in Human Egg Donation, 39 CASE W.
RES. L. REV. 1, 31 (1989); Debora Spar, The Egg Trade: Making Sense of the
Market for Human Oocytes. 365 NEW ENG. J. MED. 1289, 1289–90 (2007).
56. Korobkin, supra note 30, at 171.
57. See Stephen Minger, Interspecies SCNT-Derived Human Embryos—A
New Way Forward for Regenerative Medicine, 2 REGENERATIVE MED. 103,
103–05 (2007).
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to create normal stem cell lines. 58 ANT is a variation of SCNT
in which a genetically modified nucleus from a somatic cell is
transferred into a human oocyte. This embryo, which contains a
deliberate genetic defect, is capable of developing into a
blastocyst, but the induced defect prevents the blastocyst from
implanting in the uterus. This process has the potential to
generate customized hESCs from the blastocyst stage. 59
Human embryos with this genetic defect might lack the
capacity to develop into viable fetuses, as a result of their
inability to implant, thus providing a source of stem cells
without destroying viable embryos. Proof of concept was
obtained in mice by Meissner and Jaenisch using embryos
lacking the Cdx2 homeobox gene. 60
The viability of human embryos lacking the Cdx2 gene is
unclear, as is whether this mutation restricts human
developmental potential into certain lineages. While much
research must be done before therapeutic strategies based on
this technique could ever enter the clinic, at this time hESCs
derived from ANT can provide opportunities to study
pluripotency in hESCs, without the need for destruction of
viable embryos. The exact effects of Cdx2 gene knockout on the
development of human embryos are not well known. Opponents
contend, however, that using ANT does not overcome moral
objections to this methodology. 61
3. Parthenogenesis
Another method that focuses on oocyte stimulation and
development is parthenogenesis, or “virgin birth.” 62 This is the
reproduction method of certain amphibians, and has been used
to induce pregnancy artificially in mice. Here, an oocyte is
chemically stimulated to undergo several rounds of cell
division, as if it had been fertilized. The oocyte retains all 46

58. Alexander Meissner & Rudolf Jaenisch, Generation of Nuclear
Transfer-Derived Pluripotent ES Cells from Cloned Cdx2-Deficient Blastocysts,
439 NATURE 212, 214 (2006).
59. WB Hurlbut, Altered Nuclear Transfer as a Morally Acceptable Means
for the Procurement of Human Embryonic Stem Cells, 48 PERSP. BIOLOGY &
MED. 211, 222–26 (2005).
60. See Meissner & Jaenisch, supra note 58, at 212–14.
61. Hall, supra note 17, at 16–22; Korobkin, supra note 30, at 161, 171.
62. Kent Vrana et al., Nonhuman Primate Parthenogenetic Stem Cells,
100 PROC. NAT’L ACAD. SCI. U.S. 11911, 11911, 11916 (2003).
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chromosomes, and appears to lack developmental capacity
beyond the blastocyst stage. 63 It is uncertain whether a line
obtained by this means would be stable or whether issues
related to its parthenogenetic origin may limit its usefulness. 64
Moreover, the Dickey-Wicker Amendment includes research on
human parthenogenesis in its list of federal funding
prohibitions. 65
D. HESC WITHOUT EMBRYO DESTRUCTION: EXTRACTION AND
“DEAD” EMBRYOS
1. Extraction
Using blastomere extraction, it may be possible to extract a
single cell from embryos created for purposes of IVF, as is done
for preimplantation genetic diagnosis (PGD). 66 In 2006, Chung
et al. 67 were the first authors to report the generation of mouse
embryonic stem cell lines in this manner. Cells were taken
from eight-cell blastomeres rather than from blastocysts. The
remaining four to six cells continue to divide and multiply as
normal. 68 The cells differentiated into derivatives of all three
embryonic germ layers in vitro, as well as into teratomas in
vivo. In addition, the mouse embryos that resulted from the
biopsied blastomeres developed to term without a reduction in
their developmental potential. In PGD, the removed cells are
biopsied so that genetic testing can be performed. With
blastomere extraction, the removed cells are cultured on feeder
cells, from which stem cells can be derived. 69
Preimplantation genetic diagnosis now commonly
accompanies IVF, particularly when there is concern about

63. Id. at 11912. See generally GUIDELINES FOR HUMAN EMBRYONIC STEM
CELL RESEARCH, supra note 34.
64. Meissner & Jaenisch, supra note 53, at 213–14.
65. See Omnibus Appropriations Act, 2009, Pub. L. No. 111-8, § 509, 123
Stat. 524, 803 (2009); see supra notes 10–12 and accompanying text.
66. Irina Klimanskaya et al., Human Embryonic Stem Cell Lines Derived
from Single Blastomeres, 444 NATURE 481, 481–83 (2006).
67. Young Chung et al., Embryonic and Extraembryonic Stem Cell Lines
Derived from Single Mouse Blastomeres, 439 NATURE 216, 219 (2006).
68. Irina Klimanskaya et al., Derive and Conquer: Sourcing and
Differentiating Stem Cells for Therapeutic Applications, 7 NATURE REV. DRUG
DISCOVERY 131, 132–35 (2008).
69. See Young Chung et al., Human Embryonic Stem Cell Lines Generated
Without Embryo Destruction, 2 CELL STEM CELL 113, 113 (2008).
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inheritable disease. While some have raised concerns that the
removal of a single cell from the developing embryo for PGD
could pose significant risks to its development, so far it appears
not to have adverse effects on embryos that are later implanted
and progress to live birth. 70 Moreover, if it is clearly shown to
be safe to remove more than one cell from an embryo, in order
to use one for PGD and one for development of a stem cell
line—or, more probably, if it is reasonable to remove one cell,
grow it overnight into a blastocyst, and use one of those cells
for PGD and the rest for cell line development—then embryos
need not be destroyed to pursue hESC research. This source of
pluripotent stem cells, however, may require development to
the blastocyst stage. If blastocysts are thought to deserve
protection as future persons, then this source may be
unacceptable to hESC research opponents.
2. Dead Embryos
Another possible way to obtain pluripotent stem cells
without intentionally destroying the embryo would be to use
only those spare IVF embryos that, after achieving the four-toeight cell division, undergo “cleavage arrest” or death. 71 During
IVF, only a small proportion of zygotes produced will develop
successfully to the morula and blastocyst stages. Over half the
embryos stop dividing, and are therefore considered dead
embryos. 72 Such embryos have unequal or fragmented cells and
blastomeres and are usually discarded. While some of these
embryos show chromosomal anomalies, others appear to be
normally developed embryos from which stem cells can be
extracted. Some researchers claim that there are reliable
methods for determining whether or not the embryo has a
normal chromosome complement, while others are skeptical
about the viability of hESC lines derived from such embryos. 73
Advocates note that hESC lines derived from this method may
have broad therapeutic application for genetic conditions. Some
opponents of this method raise informed consent issues, as well
70. See Klimanskaya et al., supra note 66, at 481–84.
71. Donald W. Landry & Howard A. Zucker, Embryonic Death and the
Creation of Human Embryonic Stem Cells, 114 J. CLINICAL INVESTIGATION
1184, 1185 (2004).
72. Id.
73. Xin Zhang et al., Derivation of Human Embryonic Stem Cells from
Developing and Arrested Embryos, 24 STEM CELLS 2669, 2670 (2006).
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as ethical concerns over whether and when death actually
occurs in embryos.
IV. FUTURE PERFECT?
Those who follow the stem cell debate are familiar with its
rhythm: rapid proliferation of press information about possible
new sources of pluripotent stem cells, followed by reflexive
moral pronouncements, followed by questions about the
science, followed by clarifications, qualifications, and additional
expert views, followed by policy discussions (“Maybe we don’t
need new legislation now after all . . .”), followed by the next
round of new science. Unfortunately, the only dance that seems
to fit this rhythm is “one step forward, two steps back.” We are
not the first to argue that progress can only be made if all
reasonable lines of research are pursued as science develops. 74
Waiting for the perfect source serves simply to make the best
the enemy of the good.
But there are other reasons not to await the perfect source.
Here is one reason that is not usually offered: as we have seen
even in this brief review, a prime requirement for a “perfect”
source of pluripotent stem cells is that it have no “ethical
baggage.” 75 Physicians and scientists facing ethical issues
arising in biomedicine and research often reason that if they
wait for certainty—more facts, more information, more data—
the ethical issues will go away, having been answered by the
science.
They don’t. They never do. Science itself has values, as do
scientists. Ethics and science are always intertwined. Waiting
for perfection is a moral choice, and should be acknowledged as
such. What it means for a source of pluripotent stem cells to be
“free of ethical baggage” should be a subject of discussion. Since
all ethical issues can never disappear from scientific and
medical research, public discourse must continue as science
advances.
Research using pluripotent stem cells unquestionably
strives to alleviate significant disease burdens, and the search
74. This scientific truism has been invoked many times. With respect to
stem cells, see, for example, Jennifer Hipp & Anthony Atala, Sources of Stem
Cells for Regenerative Medicine, 4 STEM CELL REVS. & REP. 3, 9 (2008);
Zachary J. Kastenberg & Jon S. Odorico, Alternative Sources of Pluripotency:
Science, Ethics, and Stem Cells, 22 TRANSPLANTATION REVS 215, 221 (2008).
75. Constance Holden, Versatile Stem Cells without the Ethical Baggage?,
315 SCIENCE 170, 170–71 (2007).
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for pluripotent stem cell-based therapies continues to show
great promise, but the realization of effective therapies is still
far in the future; thus, it is important not to overestimate the
potential for benefit at this stage. As is the case for many new
biotechnologies, however, the development of pluripotent stem
cell science seeks a careful balance of scientific altruism and
commercial interests. It is worth noting that underlying the
arguments on all sides of the stem cell debate is some degree of
concern about the potential for commodification, either of the
person resulting from biotechnological advances or of the
human biological products that permit desired designs to be
realized. Only by acknowledging, critically examining, and
discussing the concerns that may arise from pluripotent stem
cell research can we hope to minimize its ethical and social
risks. Ultimately, science and society must face the ethical
issues openly, in order to move forward while searching for ever
more perfect sources.

